Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger M Lyons

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factorsHagop M Kantarjian, Harry P Erba, David Claxton, et al.
The New England Journal of Medicine|October 20, 2006
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITPJames B Bussel, David J Kuter, James N George, et al.
Blood|May 22, 2016
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myelomaJames R Berenson, Alan Cartmell, Alberto Bessudo, et al.
The Lancet. Haematology|April 1, 2016
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trialsMartin H Prins, Anthonie W A Lensing, Tim A Brighton, et al.
Targeted Oncology|April 29, 2024
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 StudyMichael Maris, Gilles Salles, Won Seog Kim, et al.
Cancer|January 18, 2017
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromesGuillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G Berdeja, et al.
Journal of Hematology & Oncology|February 24, 2017
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Journal of Hematology & Oncology|November 29, 2013
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet countsMoshe Talpaz, Ronald Paquette, Lawrence Afrin, et al.
British Journal of Haematology|March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Haematologica|January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factorsHagop M Kantarjian, Harry P Erba, David Claxton, et al.
The New England Journal of Medicine|October 20, 2006
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITPJames B Bussel, David J Kuter, James N George, et al.
Blood|May 22, 2016
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myelomaJames R Berenson, Alan Cartmell, Alberto Bessudo, et al.
The Lancet. Haematology|April 1, 2016
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trialsMartin H Prins, Anthonie W A Lensing, Tim A Brighton, et al.
Targeted Oncology|April 29, 2024
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 StudyMichael Maris, Gilles Salles, Won Seog Kim, et al.
Cancer|January 18, 2017
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromesGuillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G Berdeja, et al.
Journal of Hematology & Oncology|February 24, 2017
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Journal of Hematology & Oncology|November 29, 2013
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet countsMoshe Talpaz, Ronald Paquette, Lawrence Afrin, et al.
British Journal of Haematology|March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Haematologica|January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Pageof 5